Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01464931

Recruitment Status : Completed

First Posted : November 4, 2011

Results First Posted : February 19, 2016

Last Update Posted : February 19, 2016

Sponsor:

Information provided by (Responsible Party):

Amgen

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	Renal Impairment
Intervention:	Drug: Denosumab

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Severe CKD	Participants with severe chronic kidney disease (CKD; defined as creatinine clearance < 30 mL/min) received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
ESRD	Participants with end-stage renal disease (ESRD) requiring dialysis received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.

Participant Flow: Overall Study

	Severe CKD	ESRD
STARTED	16	16
COMPLETED	15	16
NOT COMPLETED	1	0
Withdrawal by Subject	1	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Severe CKD	Participants with severe chronic kidney disease (CKD; defined as creatinine clearance < 30 mL/min) received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
ESRD	Participants with end-stage renal disease (ESRD) requiring dialysis received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
Total	Total of all reporting groups

Baseline Measures

	Severe CKD	ESRD	Total
Overall Participants Analyzed [Units: Participants]	16	16	32

Age [Units: Years] Mean (Standard Deviation)	79.2 (9.5)	65.9 (12.4)	72.5 (12.8)

Gender [Units: Participants]
Female	9	7	16
Male	7	9	16

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Participants With Clinically Significant Hypocalcemia [ Time Frame: 113 days ]

Show Outcome Measure 1

2. Secondary:

Number of Participants With Hypocalcemia Determined by CTCAE v.4.0 Criteria [ Time Frame: 113 days ]

Show Outcome Measure 2

3. Secondary:

Number of Participants With Hypophosphatemia Determined by CTCAE v.4.0 Criteria [ Time Frame: 113 days ]

Show Outcome Measure 3

4. Secondary:

Number of Participants With Hypomagnesemia Determined by CTCAE v.4.0 Criteria [ Time Frame: 113 days ]

Show Outcome Measure 4

5. Secondary:

Percent Change From Baseline in Albumin-adjusted Serum Calcium Over Time [ Time Frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 5

6. Secondary:

Percent Change From Baseline in Serum Phosphorus Over Time [ Time Frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 6

7. Secondary:

Percent Change From Baseline in Serum Magnesium Over Time [ Time Frame: Baseline and Days 2, 3, 6, 8, 11, 15, 22, 29, 30, 31, 34, 36, 39, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 7

8. Secondary:

Number of Participants With Adverse Events [ Time Frame: 113 days ]

Show Outcome Measure 8

9. Secondary:

Maximum Observed Serum Denosumab Concentration (Cmax) [ Time Frame: Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 9

10. Secondary:

Time to Maximum Observed Serum Denosumab Concentration (Tmax) [ Time Frame: Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 10

11. Secondary:

Area Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1 [ Time Frame: Days 1, 8, 15, and 29 (predose) ]

Show Outcome Measure 11

12. Secondary:

Area Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2 [ Time Frame: Days 29 (predose), 36, 43, 57, 71, and 85 ]

Show Outcome Measure 12

13. Secondary:

Percent Change From Baseline in Serum C-Telopeptide Over Time [ Time Frame: Baseline and Days 1 and 29 (predose), and on Days 8, 15, 36, 43, 57, 71, 85, and 113 ]

Show Outcome Measure 13

14. Secondary:

Number of Participants Who Developed Anti-denosumab Antibodies [ Time Frame: From Day 1 (predose) to Day 113 ]

Show Outcome Measure 14

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.

Results Point of Contact:

Name/Title: Study Director
Organization: Amgen Inc.
phone: 866-572-6436

Responsible Party:	Amgen
ClinicalTrials.gov Identifier:	NCT01464931 History of Changes
Other Study ID Numbers:	20101361
First Submitted:	October 17, 2011
First Posted:	November 4, 2011
Results First Submitted:	December 14, 2015
Results First Posted:	February 19, 2016
Last Update Posted:	February 19, 2016

To Top